What is Retatrutide? The 'Triple-G' Peptide Explained
An overview of Eli Lilly's investigational triple-agonist next-generation weight loss drug, outperforming GLP-1 and dual-agonists in clinical trials.
The Evolution of Incretin Therapies
To understand why retatrutide is making headlines, you have to look at the progression of weight-loss pharmacology. Early drugs like semaglutide (Wegovy) target a single incretin hormone receptor: GLP-1. This slows gastric emptying and signals satiety.
The next generation, tirzepatide (Zepbound), targets two receptors: GLP-1 and GIP. The addition of GIP improves insulin sensitivity and has a synergistic effect on fat loss, leading to greater weight reduction than semaglutide in head-to-head trials.
Next-Generation Weight Loss Peptides
Comparing receptor targets across drug generations
| Medication | GLP-1 Target | GIP Target | Glucagon Target |
|---|---|---|---|
| Semaglutide Wegovy, Ozempic | |||
| Tirzepatide Zepbound, Mounjaro | |||
| Retatrutide (Investigational) The "Triple G" Agonist |
Retatrutide is a 'triple-hormone receptor agonist'. It targets GLP-1, GIP, and crucially, the Glucagon receptor.
Why Glucagon Matters
Historically, glucagon was thought of solely as the hormone that raises blood sugar (the opposite of insulin). However, activating the glucagon receptor also significantly increases *resting energy expenditure* (the rate at which the body burns calories at rest) and promotes lipid oxidation (fat burning) in the liver.
By combining all three, retatrutide suppresses appetite (GLP-1/GIP), improves metabolic efficiency (GIP), and actively forces the body to burn more calories (Glucagon).
Retatrutide is currently in Phase 3 clinical trials and is not yet FDA-approved. However, the Phase 2 data suggests unprecedented potency, with many patients achieving weight loss traditionally only seen with bariatric surgery.Citation: New England Journal of Medicine